

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Highly Specialised Technologies Evaluation

Emapalumab for treating primary haemophagocytic lymphohistiocytosis ID1438

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • NovImmune (emapalumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Anthony Nolan • Findacure • Genetic Alliance UK • Genetic Disorders UK • Histio UK • Metabolic Support UK • Muslim Council of Britain • Primary Immunodeficiency UK • South Asian Health Foundation • Specialised Healthcare Alliance • Together for Short Lives <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Genetic Nurses & Counsellors • Association of Paediatric Emergency Medicine • British Inherited Metabolic Disease Group • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Human Genetics • British Transplantation Society • Genomics England • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for the Study of Inborn Errors of Metabolism • UK Clinical Pharmacy Association • UK Genetic Testing Network 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • British Society of Blood and Marrow Transplantation • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division (specialised services in Scotland) • NHS Alliance • NHS Blood and Transplant • NHS Confederation • Scottish Medicines Consortium • United Kingdom National Screening Committee • Welsh Blood Service • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cell and Gene Therapy Catapult • Cancer Research UK • Cochrane Cystic Fibrosis and Genetic Disorders Group • Gene and Cell Therapy Group - UCL • Medical Research Council - Human

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	Genetics Unit <ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health Groups</u> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Evaluation Document (FED).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Evaluation Document (FED).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FED for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.